SCIENTECH (02291) announced its interim results for the six months ended June 30, 2025. Total operating revenue reached RMB 330 million, representing a year-on-year increase of 32.36%. Net profit attributable to parent amounted to RMB 182 million, up 29.81% compared to the same period last year. Basic earnings per share stood at RMB 0.5249.

According to the announcement, revenue from congenital heart disease occluder products constitutes a significant portion of the group's total revenue. Sales revenue from these products increased by 24.9% from RMB 129 million for the six months ended June 30, 2024, to RMB 161 million for the six months ended June 30, 2025, accounting for 51.6% and 48.7% of the group's total revenue for the respective periods.

The robust growth in congenital heart disease occluder product sales was primarily attributed to the steady growth in revenue from the group's traditional metal occluder products, combined with the successful certification and rapid commercialization of the group's fourth-generation MemoSorb® biodegradable ventricular septal occluder and atrial septal defect occluder, which generated substantial incremental revenue. The group is also leveraging biodegradable technology to achieve product iteration and establish a differentiated competitive landscape.